Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
DHAKA - Beximco Pharmaceuticals Limited announced Monday that the High Court decision regarding the Bangladesh Securities and Exchange Commission’s proposed appointment of nine additional independent non-executive directors to the company’s board will likely be delayed until November 2025.
The delay stems from the High Court’s current summer vacation closure, which continues until October 19, according to a statement from the fast-growing generic pharmaceutical manufacturer. Upon the court’s reopening, Beximco plans to seek acceleration of the hearing.
This update follows the company’s previous statement on May 21, 2025, regarding the BSEC Order that would significantly alter the composition of Beximco’s board of directors.
The London Stock Exchange-listed company (AIM:BXP) indicated it will make additional announcements as appropriate regarding the ongoing legal matter.
Beximco Pharmaceuticals, founded in 1976, manufactures and exports generic pharmaceutical products and active pharmaceutical ingredients. The company maintains manufacturing facilities certified by regulatory authorities in the United States, Europe, Australia, Canada, and other regions, with a presence in more than 50 countries.
This article is based on information contained in a press release issued by Beximco Pharmaceuticals Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.